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BACKGROUND: Atrophy of skeletal muscle in cancer cachexia has been attributed to a tumour-produced highly glycosylated peptide
called proteolysis-inducing factor (PIF). The action of PIF is mediated through a high-affinity membrane receptor in muscle. This study
investigates the ability of peptides derived from the 20 N-terminal amino acids of the receptor to neutralise PIF action both in vitro
and in vivo.
METHODS: Proteolysis-inducing factor was purified from the MAC16 tumour using an initial pronase digestion, followed by binding on
DEAE cellulose, and the pronase was inactivated by heating to 801C, before purification of the PIF using affinity chromatography.
In vitro studies were carried out using C2C12 murine myotubes, while in vivo studies employed mice bearing the cachexia-inducing
MAC16 tumour.
RESULTS: The process resulted in almost a 23000-fold purification of PIF, but with a recovery of only 0.004%. Both the D- and L-forms
of the 20mer peptide attenuated PIF-induced protein degradation in vitro through the ubiquitin-proteosome proteolytic pathway and
increased expression of myosin. In vivo studies showed that neither the D- nor the L-peptides significantly attenuated weight loss,
although the D-peptide did show a tendency to increase lean body mass.
CONCLUSION: These results suggest that the peptides may be too hydrophilic to be used as therapeutic agents, but confirm the
importance of the receptor in the action of the PIF on muscle protein degradation.
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Half of all cancer patients experience a progressive loss of body
mass due to depletion of adipose tissue and skeletal muscle. This
process, called cachexia, is estimated to be responsible for at least
20% of cancer deaths through cardiac/respiratory failure (Inagaki
et al, 1974) and the patients quality of life is also reduced through
immobility. Tissue wasting is progressive and extensive, with loss
of 85% of adipose tissue and 75% of skeletal muscle mass, when
the weight loss reaches 30%, which is close to death (Fearon, 1992).
To provide appropriate therapy, it is necessary to understand
the mechanism of tissue atrophy in cachexia. A number of factors,
including cytokines such as tumour necrosis factor-a (Oliff et al,
1987) and interleukin-6 (Strassman et al, 1992), have been
implicated as playing a role in the development of cachexia. In
addition, our own studies have shown that those tumours that
initiate muscle atrophy produce a novel sulphated glycoprotein of
Mr 24000 called proteolysis-inducing factor (PIF; Todorov et al,
1996a), which induces muscle wasting, both by depressing protein
synthesis and by increasing protein degradation (Lorite et al,
1997). Protein degradation induced by PIF is mediated through an
upregulation of the expression and activity of the ubiquitin-
proteasome proteolytic pathway, which is considered to have the
major role in the degradation of skeletal muscle in cachectic cancer
patients (Lorite et al, 1998). The central mediator for the
depression of protein synthesis and induction of protein degradation
induced by PIF is phosphorylation of the RNA-dependent protein
kinase (PKR) (Eley and Tisdale, 2007). Autophosphorylation of
PKR causes activation, resulting in phosphorylation of its substrate
eukaryotic initiation factor-2 on the a-subunit, leading to
inhibition of translation initiation by preventing binding of the
initiator methionyl-tRNA to the 40S ribosomal subunit. Activation
of PKR also initiates protein degradation through the ubiquitin-
proteasome pathway by increasing nuclear binding of the
transcription factor nuclear factor-kB (Eley and Tisdale, 2007).
The action of PIF is mediated through an Mr 40000 membrane
receptor with high affinity (Kd 2.1–21nmoll
 1) present on muscle
and liver, but not on kidney or adipose tissue (Todorov et al,
2007). Antisera reactive to a 19mer corresponding to the
N-terminal amino acids of the PIF receptor was effective in
attenuating weight loss in mice bearing the cachexia-inducing
MAC16 tumour, through an increase in lean body mass, attributed
to an increase in protein synthesis and decrease in degradation in
skeletal muscle.
This study investigates the possibility of using the PIF receptor
N-terminal 20mer to neutralise PIF action in vitro, as well as its
ability to neutralise muscle atrophy in mice bearing the MAC16
tumour. Both the D- and L-versions of the peptide were
investigated, as the D-form would be resistant to proteolytic
cleavage and more suitable for in vivo studies. This study also
reports a new method for the preparation of PIF from the MAC16
tumour, because of the reported difficulties in the isolation and
identification of PIF (Wieland et al, 2007).
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Materials
Fetal calf serum (FCS), horse serum (HS), and Dulbecco’s modified
Eagle’s medium (DMEM) were purchased from Invitrogen
(Paisley, UK). L-[2,6-
3H] phenylalanine (sp.act.37 Bqmmol
 1)
was from American Radiolabelled Chemicals (Cardiff, UK). Mouse
monoclonal antibodies to 20S proteasome a-subunits and p42 were
from Affiniti Research Products (Exeter, UK) and mouse mono-
clonal antibody to myosin heavy-chain type II was from
Novocastra (via Leica Biosystems, Newcastle, UK). Polyclonal
rabbit antibody to mouse b-actin was purchased from Sigma-
Aldrich (Dorset, UK). Peroxidase-conjugated sheep antirabbit and
antimouse antibodies were purchased from GE Healthcare (Bucks,
UK), as were Hybond A nitrocellulose membranes. Enhanced
chemiluminescence (ECL) development kits were from Pierce
through Thermo Fischer Scientific (Northumberland, UK). The
D- and L-amino-acid versions of the N-terminal 20 amino acids of
the PIF receptor Asp-Ile-Asn-Gly-Gly-Gly-Ala-Thr-Leu-Pro-Gln-
Lys-Leu-Tyr-Leu-Ile-Pro-Asn-Val-Leu were synthesised by Severn
Biotech Ltd (Worcs, UK). For the D-amino-acid version, the amino
acids were in the reverse order, so that the Leu became the
N-terminal amino acid and the Asp the C-terminal.
Animals
Fragments (1 2mm) of the MAC16 tumour, obtained from donor
animals with maximum weight loss, were implanted s.c. into the
flank of pure strain male NMRI mice, obtained from our own
inbred colony, by means of a trochar, as previously described
(Bibby et al, 1987), Animals were fed a rat and mouse breeding diet
(Special Diet Services, Witham, UK) and water ad libitum, and
weight loss was evident 12–15 days after transplantation when the
tumour became palpable. When the mice had lost B5% of their
starting body weight they were randomised into groups of six to
receive either D-o rL-peptide or solvent (PBS) administered daily
by i.v. injection. Both tumour volume and body weight were
monitored daily and animals were terminated by cervical
dislocation when the body weight loss reached 20%. All animal
experiments followed a strict protocol approved by the British
Home Office, and the ethical guidelines that were followed met the
standards required by the UKCCR guidelines (Workman et al,
1998). After termination by cervical dislocation, the body
composition was determined as previously described in detail
(Russell et al, 2004). Carcasses were heated at 80–901C for 48h, or
until a constant weight was achieved and the water content was
determined as the difference between the wet and dry weights.
Lipids were extracted with chloroform/methanol (1:1), ethanol/
acetone (1:1) and diethyl ether and after evaporation of the
solvent the fat content was determined from the weighed residue.
The non-fat carcass mass was calculated as the difference between
the initial weight of the carcass and the weight of water and fat.
Cell culture
C2C12 murine myoblasts were maintained in vitro in DMEM
supplemented with 10% FCS and glutamine under an atmosphere
of 10% CO2 in air at 371C. When the myoblasts reached about 80%
confluency they were differentiated into myotubes in DMEM
containing 2% HS, with medium changes every 2 days. Differ-
entiation was complete in 3–5 days, and the myotubes remained
viable for a further 4–5 days.
Measurement of total protein degradation
This was performed as previously described (Whitehouse and
Tisdale, 2003). Briefly, myotubes were labelled for 24h with
L-[2,6-
3H] phenylalanine and then washed extensively in PBS
followed by a further incubation for 2h to eliminate degradation of
short-lived proteins. Protein degradation was determined over a
24-h period in the presence of 2mM non-labelled phenylalanine to
prevent reincorporation of radioactivity, as a fraction of the total
radioactivity incorporated into the myotubes.
Measurement of proteasome activity
The functional activity of the 20S proteasome was determined as
the ‘chymotrypsin-like’ enzyme activity, as previously described in
detail (Whitehouse and Tisdale, 2003). Activity was determined by
the release of aminomethyl coumarin (AMC) from the fluorogenic
peptide succinyl-LLVY-AMC in the absence and presence of the
specific proteasome inhibitor lactacystin (10mM). Only lactacystin-
suppressible activity was considered to be proteasome specific.
The activity was normalised to the protein content, which was
determined using a standard colourimetric protein assay (Sigma,
Dorset, UK).
Purification of PIF
Solid MAC16 tumours (5g) were homogenised in 25ml 10mM Tris-
HCl, pH 8.0, on ice, and incubated with pronase (1mgml
 1)
o v e r n i g h ta t3 7 1C. The soup was centrifuged at 4000g for 15min to
remove the pellet, and the supernatant was concentrated to a volume
of 1ml against PBS using an Amicon Ultra-15 centrifugal filter
(Millipore, Cork, Rep of Ireland) with a molecular weight cutoff
of 1000. DEAE cellulose (2g), previously washed with 100mM
Tris-HCl, pH 8.8 for 30min and 10mM T r i s - H C l ,p H8 . 8f o ra n o t h e r
30min, was resuspended in 20ml 10mM Tris-HCl, pH 8.8, and was
incubated with the protein concentrate for 2h at room temperature.
The PIF bound to the DEAE cellulose, which was sedimented by
centrifugation at 4000g for 15min, and the PIF was eluted with 0.3M
NaCl in 20ml 10mM Tris pH 8.8, by incubation for 30min. The DEAE
cellulose was removed by centrifugation at 4000g for 15min, and the
supernatant was concentrated to 1ml against PBS using an Amicon
Ultra-15 centrifugal filter with a molecular weight cutoff of 10000.
Proteolysis assays suggested that t h ec o n c e n t r a t es t i l lc o n t a i n e d
pronase. To inactivate this, the sample was heated to 801Cf o r1 5m i n .
Two methods were investigated for the isolation of PIF: (1) Wheat
germ agglutin agarose, based on the observation (Todorov et al,
1996b) that this lectin will bind the oligosaccharide chains of PIF. The
s a m p l ew a sl o a d e do n t ot h ec o l u m na n dw a s h e dw i t h1 0 m M Tris-
HCl, pH 7.4 and eluted with 0.1mM N-acetylglucosamine. (2) Affinity
chromatography using anti-PIF monoclonal antibody coupled with
protein A on an Affi-Gel column. The retained proteins were eluted
with 100mM glycine-HCl, pH 2.5, as described (Todorov et al, 1996b).
Western blotting
Samples of cytosolic protein (5–15mg), formed by centrifugation
of cellular homogenates from the ‘chymotrypsin-like’ enzyme
activity at 18000g for 10min at 41C, or from steps in the
purification of PIF, were resolved on 12% SDS–PAGE at 180V for
B1h, followed by transference onto 0.45mm nitrocellulose
membranes. These were blocked with 5% Marvel in Tris-buffered
saline, pH 7.5, for 1–2h at room temperature (20S, p42) or at 41C
overnight. Both primary and secondary antibodies were used at a
dilution of 1:1000 except for myosin (1:40). Incubation was for
2h at room temperature and development was by ECL. Blots were
scanned by a densitometer to quantify differences.
Statistical analysis
Data are presented as mean values±s.e. for at least three replicate
experiments. Differences in mean values between groups were
determined by one-way ANOVA followed by Tukey–Kramer
multiple comparison test. P-values o0.05 were considered
significant.
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A new purification scheme has been devised for PIF, the steps and
yields of which are given in Table 1. Initially, the MAC16 tumour
homogenate was subjected to pronase digestion, because PIF,
unlike the majority of tumour proteins, is not affected by pronase,
being predominantly carbohydrate in composition (Todorov et al,
1996a). Proteolysis-inducing factor can be recovered from the
digest by binding to DEAE cellulose (Figure 1A), as the molecule
has a high overall negative charge, but enzyme assays showed co-
purification with the pronase, which would preclude further
purification by affinity chromatography. To overcome this
problem, the pronase was inactivated by heating at 801C for
15min, after which time western blotting revealed that the PIF was
not destroyed by this treatment (Figure 1A). This allowed a final
purification of PIF by affinity chromatography using an anti-PIF
monoclonal antibody (Figure 1B) giving an overall purification of
22936-fold (Table 1). Alternatively, the PIF can be purified by
lectin affinity chromatography using wheat germ agglutinin
agarose and elution with N-acetylglucosamine (Figure 1). However,
the capacity of this type of affinity chromatography was less than
with antibody and some of the PIF came through with the column
washings (Figure 1).
To determine the ability of the N-terminal 20mer of the PIF
receptor to attenuate protein degradation induced by PIF,
experiments were conducted in murine myotubes as a surrogate
model of skeletal muscle. A dose–response curve for total protein
degradation induced by PIF in murine myotubes in the absence
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Figure 2 Effect of receptor peptides on protein degradation by PIF in
C2C12 myotubes. (A) Total protein degradation after 24h in response to
PIF alone (’) or in the presence of the L-receptor peptide (&) (10mM)
added 2h before the addition of PIF. (B) Comparison of D- and L-peptides
(both 10mM) and anti-PIF antibody (10mgml
 1) on protein degradation
induced by PIF (4.2nM) over a 24-h period. (C) Effect of the D- and
L-peptides (both 10mM) on the proteasome ‘chymotrypsin-like’ enzyme
activity in response to PIF (4.2nM) after 24h incubation. The experiment
was repeated three times. Differences from control are indicated as a,
Po0.05; b, Po0.01; or c, Po0.001, while differences between groups are
indicated as d, Po0.05; e, Po0.01; or f, Po0.001.
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Figure 1 Purification of PIF from the MAC16 tumour (A) The tumour
homogenate (lane 1) was incubated with pronase (1mgml
 1) overnight at
371C, and the PIF was concentrated by binding to DEAE cellulose (lane 2).
Pronase was inactivated by heating to 801C for 15min (lane 3). The PIF
was purified by affinity chromatography using either anti-PIF antibody (B)
or WGA (C). In (C) lane 1 shows the tumour extract after heating to
801C, lane 2 shows material not adherent to the WGA column while lane
3 shows retained material eluted with 10mM Tris-HCl, pH 7.4 containing
0.1M N-acetylglucosamine as for purification of the PIF receptor (Todorov
et al, 2007). The figures are western blots using the anti-PIF monoclonal
antibody (Todorov et al, 1996b)
Table 1 Purification of PIF from solid MAC16 tumours
Stage
Protein
(mg)
Recovery
(%)
Purification
(fold)
Tumour homogenate 2500 — —
Pronase digest 564 22.56 4.4
DEAE cellulose 2.1 0.08 1190
Heat to 801C 2.0 0.08 1190
Affinity chromatography
(antibody)
0.109 0.004 22936
Abbreviations: DEAE¼diethylamino ethylcellulose; PIF¼proteolysis-inducing factor.
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sand presence of the L-peptide is shown in Figure 2A. There was not
a significant difference in protein degradation at concentrations of
PIF between 2.1 and 10.5nM, and the bell-shaped dose–response
was less pronounced than in previous studies (Whitehouse and
Tisdale, 2003). However, PIF was used for all further in vitro
studies at a concentration of 4.2nM to maintain continuity with
other investigations. Protein degradation by PIF was completely
attenuated by the L-peptide at all concentrations of PIF
(Figure 2A). The D-peptide also attenuated total protein degrada-
tion in myotubes, as did the anti-PIF antibody (Figure 2B). To
determine if the effect on total protein degradation was due to
attenuation of the ubiquitin-proteasome pathway, functional
activity was measured as the ‘chymotrypsin-like’ enzyme activity.
As with total protein degradation PIF increased the ‘chymotrypsin-
like enzyme activity (Figure 2C), and this was attenuated by both
the D- and L-forms of the receptor N-terminal 20mer. Further
support for the involvement of the ubiquitin-proteasome pathway
was provided by the attenuation, by both the D- and L-forms of the
receptor peptide, of the PIF-induced increase in the expression of
the 20S proteasome a-subunits (Figure 3A), p42, an ATPase
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100
c
150
MuRF1
50
Actin
c c
PIF (4.2 nM)
L-peptide (10 M)
D-peptide (10 M)
–
–
–
+
–
–
+
+
–
+
–
+
PIF (4.2 nM)
L-peptide (10 M)
D-peptide (10 M)
MAFbx
PIF (4.2 nM)
L-peptide (10 M)
D-peptide (10 M)
–
–
–
+
–
–
+
+
–
+
–
+
PIF (4.2 nM)
L-peptide (10 M)
D-peptide (10 M)
–
–
–
+
–
–
+
+
–
+
–
+
150
200
250 c
f
0
50
NC
PIF
PIF + L-peptide
PIF + D-peptide
NC
PIF
PIF + L-peptide
PIF + D-peptide
NC
PIF
PIF + L-peptide
PIF + D-peptide
NC
PIF
PIF + L-peptide
PIF + D-peptide
D
e
n
s
i
t
o
m
e
t
r
y
(
%
 
c
o
n
t
r
o
l
)
D
e
n
s
i
t
o
m
e
t
r
y
(
%
 
c
o
n
t
r
o
l
)
D
e
n
s
i
t
o
m
e
t
r
y
(
%
 
c
o
n
t
r
o
l
)
D
e
n
s
i
t
o
m
e
t
r
y
(
%
 
c
o
n
t
r
o
l
)
D
e
n
s
i
t
o
m
e
t
r
y
(
%
 
c
o
n
t
r
o
l
)
f
Actin
19S
200
250
300
350
400
450
e
f
0
50
100
Actin
250
100
150
200
f
c
0
Actin
–
+
+ + +
––
–––
–
+
140
160 c
40
60
80
100
120
f f
0
20
Actin
Myosin
PIF (nM)
100
120 f f
c c
f f
20
40
60
80
0
0
PIF (nM)
16.8 10.5 4.2 2.1 0 16.8 10.5 4.2 2.1 0
L-peptide (10 M) + + + + + – – – – –
16.8 10.5 4.2 2.1
Figure 3 Effect of PIF-receptor peptides on expression of components of the ubiquitin-proteasome pathway in the presence of PIF (4.2nM). Western
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promoting E3 ligases MuRF1 (Figure 3C), and MAFbx/atrogin-1
(Figure 3D). Myotubes treated with either the D-o rL-forms of the
peptide also showed an increase in expression of the myofibrillar
protein myosin (Figure 3E). These results suggest that the PIF
receptor N-terminal peptides may be effective in the attenuation of
muscle wasting in cachexia.
To determine if this was correct mice bearing the MAC16
tumour were treated daily with either the L-o rD-peptide at dose
levels up to 100mg per mouse by i.v. injection. The L-peptide was
completely ineffective in the attenuation of the loss of body weight,
while the D-peptide-treated animals showed a reduced rate of
weight loss (Figure 4A), but this did not reach statistical
significance. There was also a tendency to increase lean body
mass (D-peptide 22.1±1.5% vs PBS 17.4±1.9%; P¼0.09), but
again this did not reach statistical significance. There was a small
but statistically significant reduction in tumour growth after 6 days
treatment with the D-peptide (Figure 4B), but there was no effect
with the L-peptide. These results suggest that the peptides may be
too hydrophilic to be used as therapeutic agents.
DISCUSSION
Proteolysis-inducing factor is a sulphated glycoprotein with a short
central polypeptide chain, which is derived from dermicidin
(Schittek et al, 2001), to which are attached sulphated oligosac-
charide residues through both N- and O-glycosidic linkages
(Todorov et al, 1997). It is strongly catabolic to skeletal muscle
by depressing protein synthesis and increasing protein degrada-
tion through the ubiquitin-proteasome proteolytic pathway (Eley
and Tisdale, 2007). Its presence in urine (Cariuk et al, 1997;
Williams et al, 2004) and tumours (Cabal-Manzano et al, 2001) is
strongly correlated with the development of cachexia in cancer
patients. However, a study in patients with metastatic gastric/
oesophageal cancer based on western blotting of urine extracts
(Wieland et al, 2007) has questioned the role of PIF in weight loss.
It is questionable whether these investigators were actually
measuring PIF, since the material was relatively abundant, and
previous studies (Cariuk et al, 1997) had shown PIF to represent
just 5 10
 4 percent of the total urinary proteins. The material
was later identified as immunoglobulin light chain, which cross-
reacted with the anti-PIF antibody. This antibody has been shown
to be reactive to the carbohydrate chains of PIF (Todorov et al,
1997), and may crossreact with other oligosaccharides having a
similar antigenic determinant. However, a more recent study
(Wang et al, 2010) in patients with non-small cell lung cancer
using immunohistochemical staining with the same antibody
identified PIF in cancer, but not in normal tissue. The positive rate
of PIF expression (90%) was significantly higher in patients
with weight loss, than those without, and PIF expression was
negatively related to survival in medium to advanced stages of
disease (II–IV).
To overcome problems with western blotting of PIF, this study
reports a new method for the purification of PIF from the MAC16
tumour, which could also be adapted to western blotting of urine
extracts. This method is simple and overcomes the problems
associated with the purification of a molecule which is only present
in tumours at 1 part per 10
7 of the total tumour protein (Todorov
et al, 1996a). It utilises the unique characteristics of PIF as a
sulphated glycoprotein, which is resistant to pronase and heat
denaturation (Todorov et al, 1996a). This enables the major
tumour proteins to be digested giving a 22936-fold purification
after extraction of PIF by DEAE cellulose (Table 1). It is likely that
the oligosaccharide chains in PIF bind around the core peptide
protecting it from both heat and proteolytic degradation. A final
purification can be achieved by affinity chromatography using
either Triticum vulgaris (wheat germ agglutinin), which has been
shown by lectin blotting studies to show a strong reaction with
PIF (Todorov et al, 1996b), or anti-PIF monoclonal antibody,
previously employed in purification studies (Todorov et al, 1996b).
The PIF produced by this scheme was biologically active and
induced protein degradation in murine myotubes at the same
concentration as that previously employed (Whitehouse and
Tisdale, 2003).
Previous studies (Todorov et al, 2007) have shown that antisera
raised against the N-terminal portion of the PIF receptor
effectively attenuate protein degradation induced by PIF in vitro
and protected atrophy of skeletal muscle in mice bearing the
cachexia-inducing MAC16 tumour. This occurred through binding
of antibody to the receptor, which would sterically exclude PIF
from binding. This study reports a similar phenomenon with both
the D- and L-forms of the N-terminal 20mer of the PIF receptor,
which therefore must be the site to which PIF binds. However,
studies in mice bearing the MAC16 tumour show that the peptides
were less effective at blocking weight loss than the antibody,
possibility due to their hydrophilic nature, which would promote
rapid excretion. Despite this the ability of the peptides to block PIF
action in vitro confirms that the N-terminal region of the receptor
is responsible for binding of PIF initiating the signalling pathway
leading to protein degradation through the ubiquitin-proteasome
proteolytic pathway.
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